Xarelto Lawsuit Update: New Xarelto MDL Pretrial Order Released

November 16, 2015 – – BloodThinnerHelp.com reports today with an update from the Xarelto multidistrict litigation. On October 21, 2015, Pretrial Order 15B was released by presiding Judge Eldon Fallon. The order is in regards to the preservation of voice mail, text messages, and instant messages that may be pertinent to the Xarelto litigation. More specific information about the ongoing Xarelto litigation can be found on this page.

Specifically, in Pretrial Order 15, the plaintiffs and defendants agreed that the parties will continue to meet and discuss their obligation that all parties have to preserve relevant voicemails, instant messages set or received on an instant messaging system, or text messages sent or received on a cellular phone, smartphone, tablet, or other mobile device for the trial. The full Pretrial Order can be found online here.

Details of the Xarelto MDL:

The Xarelto MDL was formed in December 2014 after a motion was made to consolidate the rising number of cases filed against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals. Consolidating the cases in the MDL is a way to save time and judicial resources for all parties involved. It streamlines the pretrial discovery and trial processes. The lawsuits were able to be consolidated into this litigation management system because they all made similar allegations against the same defendants. These lawsuits are alleging that the blood thinner Xarelto causes serious internal bleeding which can lead to severe, life changing injuries and even death in some patients. Further, they allege that the manufacturers failed to adequately warn patients about the true dangers of the drug and that they were negligent in releasing the drug to market without a corresponding antidote. The lawsuits allege that this is what makes Xarelto particularly dangerous, more dangerous than the other blood thinners available on the market.

Lawsuits Allege Xarelto’s Lack of Antidote is Dangerous:

Unlike traditional blood thinners available on the United States drug market, such as Warfarin, Xarelto does not have a corresponding antidote to reverse its anticoagulant effects. This is dangerous because if a patient taking Xarelto suffers from an internal bleeding injury, there is no medical way to stop the bleeding short of extreme live saving measures. This is very different for patients who are taking traditional blood thinners, like warfarin, and experience an internal bleed. In that event, a doctor can simply administer vitamin K and the patient’s blood will clot again.

For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

ReleaseID: 60005476